Levofloxacine Fresenius Kabi (Levofloxacin Hemihydrate)

Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA supercoiling and separation during replication. By blocking these targets, the drug prevents bacterial DNA synthesis and transcription, leading to rapid bacterial cell death. Its concentration‑dependent killing makes it effective against many resistant organisms.

The specific dose and duration are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local antimicrobial guidelines. Levofloxacine Fresenius Kabi is supplied as an injectable product, and the healthcare professional will calculate the appropriate infusion rate and total daily amount.

Safety data for levofloxacin during pregnancy and lactation are limited. The drug is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should assess each case individually and consider alternative agents with a more established safety profile for pregnant or nursing patients.

Enquiries are submitted through the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Levofloxacin offers a broad spectrum of activity similar to other fluoroquinolones but has enhanced potency against Gram‑positive organisms and a convenient once‑daily dosing schedule when given orally. Compared with macrolides or beta‑lactams, it provides superior penetration into respiratory tissues and a lower risk of bacterial resistance in certain settings, though safety considerations differ.

The product must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to administration, the solution is allowed to reach room temperature and inspected for particulate matter or discoloration.

Levofloxacine Fresenius Kabi is given by intravenous infusion. The prescribed dose is diluted in an appropriate compatible IV fluid and infused over a period defined by the treating physician, typically ranging from 30 minutes to 1 hour, depending on the clinical scenario and patient tolerance.

Serious adverse events include tendon rupture (especially Achilles), QT‑interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should be monitored for musculoskeletal pain, cardiac symptoms, and any signs of severe skin reactions throughout treatment.

Levofloxacine Fresenius Kabi is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any of the product excipients. Caution is also advised for patients with a history of tendon disorders, uncontrolled seizures, or those receiving other QT‑prolonging medications. The drug should be avoided in these populations unless no suitable alternatives exist.